Browse studies

Find your next paid study

3,226 recruiting studies matching your filters

His Bundle Pacing in Bradycardia and Heart Failure

Participants in this study will either have heart failure (HF) and are scheduled to undergo pace maker (PM) implantation, cardiac resynchronization therapy pac…

BradycardiaHeart Failure

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Yong-Mei ChaNCT03008291

Phase 2

Whole Versus Partial Gland Boost During Prostate SBRT (Gland Boost)

This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during p…

Prostate CancerProstate Adenocarcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of NebraskaNCT07574489

Phase 3

Randomized Controlled Trial of Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery

Orthopedic wrist procedures often cause significant postoperative pain. A supraclavicular nerve block is an effective and proven method to help reduce postoper…

Distal Radius FracturesWrist Fractures

Estimated

~$50 – $1,500

Actual pay is set by the research site.

University of North Carolina, Chapel HillNCT06179004

Phase 1

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatme…

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Institute of Neurological Disorders and Stroke (NINDS)

Phase 1

Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab…

Head and Neck Squamous Cell CarcinomaHPV-Negative Squamous Cell Carcinoma

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Washington University School of MedicineNCT07552558

Phase 1

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary eff…

Esophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

IDEAYA BiosciencesNCT07503808

Observational

Next4You: : A Fully Mobile Relationships Based Program for Youth in Foster Care

The purpose of the study is to rigorously evaluate Next4You, an innovative, fully mobile program featuring 6 content modules, each containing 8-10 microlessons…

Estimated

~$10 – $1,125

Actual pay is set by the research site.

ETR AssociatesNCT06127277

Observational

Ototoxicity Monitoring and Remote Audiometry

This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hea…

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Cutaneous Squamous Cell Carcinoma of the Head and NeckHead and Neck Carcinoma of Unknown Primary+30 more

Phase 1

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors…

Metastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8+3 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05372614

Phase 1

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in pati…

Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-muscle Invasive Bladder Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

enGene, Inc.NCT04752722

Phase 3

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES): Implementation of an Opioid-free Multimodal Analgesia Discharge Pathway

This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribin…

Opioid Consumption, PostoperativeMultimodal AnalgesiaRobotic Assisted Laparoscopic Surgery+2 more

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Brigham and Women's HospitalNCT07427043

Phase 2

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or …

Nonmuscle-invasive Bladder Cancer

Estimated

~$75 – $2,800

Actual pay is set by the research site.

ImmVira Pharma Co. LtdNCT06971614